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CHAPTER 1: INTRODUCTION
A challenge facing many scientists today is the discovery of biomarkers for health
benefits and disease diagnosis. Advances in this area have occurred from the realization that the
focus should shift from the identification of single biomarkers to the identification of complex
and dynamic biomarker patterns. Current research supports the capacity and need for molecular
biomarkers that allow early detection of onset of disease or ideally, the pre-diseased state [1].
Identification of biomarker patterns, although complex to analyze, will be essential for answering
questions related to the etiology and progression of disease states.
Technological advances in biological sciences over the past few years have created a new
era of research including the emerging field of systems biology. Systems biology can be
described as a “scientific field that endeavors to quantitatively characterize the genetic,
transcription, protein, metabolic signaling and other information pathway responses to a clearly
defined perturbation of a biological system and to assess their interactions and integrate that
information into graphical network models that serve as predictive hypothesis to explain
emergent behaviours” [2].

The comprehensive investigation of genomics, transcriptomics,

proteomics, and metabolomics are important building blocks and will play a central role in
studying organisms using a biological systems approach.
Metabolomics is an emerging field with tremendous potential for advancing our
understanding of human health, disease progression and development of personalized medical
interventions. Assessment of a biological system through metabolomic approaches provides the
investigator with molecular information that is close to phenotypes in question because
metabolites are a product of gene, mRNA and protein activity [3].
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Metabolic disorders cause alteration in the metabolic regulatory system which are the
cause for many human diseases such as obesity and type 2 diabetes mellitus. The pathological
development involves altered expression of low molecular weight metabolites including lipids
and amino acids, and carbohydrates such as glucose. Changes in the metabolic profile related to
the progression of diabetes are complex, arising from the interaction between many genetic and
environmental factors. An improved understanding of biological systems at the molecular level
is anticipated to result from metabolomics.
METABOLOMICS
Metabolomics is the rapidly evolving field of the comprehensive measurement of ideally
all endogenous metabolites in a biological fluid [4][5][6][7][8][9]. One of the important main
applications of metabolomics within the clinical and pharmacological disciplines lies in the
discovery of biomarkers to diagnose health status, disease or outcome of pharmacological
treatment [3]. The metabolome represents an immense number of components that belong to a
wide variety of compound classes, such as amino acids, lipids, and organic acids.

These

compounds are diverse in their physical and chemical properties and are present in varying
concentration range [10]. A major advantage in the application of metabolomics stems from an
improved ability to detect up to many hundreds of metabolites in parallel, which provides an
efficient method for monitoring altered biochemistry [11].
Changes in metabolic profiles are a potential source of such biomarkers [12][13][14][15].
The research shows that there is a general consensus that the metabolome describes the total sum
of metabolites in a given biological sample. Due to the complex functions of a large number of
different cellular components, a fundamental problem exists with the interpretation of the results
from the analysis [16]. With emerging analytical techniques like nuclear magnetic resonance
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(NMR) and mass spectroscopy (MS), data on metabolites, nutrients and other compounds in biofluids can be acquired with more accuracy and precision.
Metabolites
Living cells have energy and building blocks required for growth and maintenance from
the conversion of small chemical compounds to another set of chemical compounds with lower
free energy content [17]. The metabolism involves the chemical reactions with many different
chemical intermediates, and the chemicals involved in the metabolism are called metabolites.
Despite the number of metabolites that participate in the metabolism, there is a high degree of
organization of the different inter conversion processes.
Metabolites are intermediates for biochemical reactions and play an essential role in
connecting many different pathways that operate within a living cell. They are the by-products
of enzyme-catalyzed reactions that occur naturally within living cells [17]. As the intermediates
of biochemical reactions, metabolites play an important role in connecting many different
pathways that operate a living cell [17]. Thus, metabolites represent integrative information of
the cellular function and it defines the phenotype of the cell or tissue in response to genetic or
environmental changes [3].
The analysis of metabolites presents challenges because each metabolite is characterized
by its individual structure.

Metabolites are unique, their role is specific and metabolites from

the same pathway can present different chemistry. Due to the diversity in physical and chemical
properties currently an assortment of analytical techniques allowing the comprehensive analysis
of metabolites is required.
Primary metabolites are found in all organisms and are an integrate part of essential life
processes. These metabolites are involved in energy and production of core structures in the
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cells for example, glycolysis, respiration or photosynthesis. These metabolites are building
blocks and energy sources like proteins, nuclear acids or polysaccharides which belong to
primary metabolism. These metabolites are influenced by the nutritional status of the organism
and are similar across species. Secondary metabolites on the other hand, have only restricted
distributions and often will have specific characteristics of individual organisms and species.
Secondary metabolites do not participate in growth and development and therefore are not
considered essential for life. These metabolites often have an unknown function and require
genes to be produced [17].
It is thought that the human body contains approximately 3000-5000 detectable
metabolites, a sizable fraction of which have been identified [18]. It is estimated the number of
metabolites is lower than the number of all genes and protein in a cell. At this time, it is difficult
to determine the number of metabolites and also other cell products such as transcripts and
protons at a given time in a specific cell because the analytical techniques are not available [7].
The concentrations of metabolites are dependent on several factors including the
environment, whether its an intermediate or end product, cell status, or turnover rate. Therefore,
some metabolites will be highly abundant and others will be available in trace amounts which
impacts the analytical technique used by the investigator.

The dynamic range which exists in

metabolites for any given biological system contributes to complexity of the analysis.
Metabolomic analysis includes the identification and quantification of all intracellular and
extracellular molecules that have a mass lower than 1000 DA using different analytical
techniques [16].
The metabolome consists of metabolites which vary widely in chemical structures and
properties. The levels of each metabolite are dependent on the physiological, developmental and
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pathological state of a cell, tissue or organism. Thus, the metabolic profile of biological
specimens are affected by numerous factors such as age, diet, ethnicity, drugs, lifestyle or gut
microfloral populations which contribute to the complexity to obtain information specific to a
disease [19]. As, metabolites have a rapid turnover rate, sample preparation is a crucial step in
the analysis due to high turnover rate.
Sample preparation is considered a limiting step in metabolomic analysis because the
concentration of metabolites can change very rapidly. Because the metabolome represents a
‘snapshot’ of the in vivo metabolic state of a cell or organism in a specific developmental and
environmental condition, rapid quenching is crucial to stop a reaction at a given time. This will
minimize the formation or degradation of metabolites after sampling due to remaining enzymatic
activity or oxidation. Quenching can usually be achieved through a change in pH and
temperature [10]. One advantage of utilizing metabolomics in nutrition is that there are several
accessible body fluids that contain possible biomarkers in the human body. Biofluids provide a
window into the biochemical status of a living organism. Urine and blood (serum or plasma) are
the most commonly used biofluids for metabolomics based studies because they contain
detectable metabolites that can be obtained non or minimally invasively [10]. Compared to other
biofluids, urine offers low concentration of protein and a high concentration of low molecular
weight compounds which results in high quality measurements due to narrow line widths of the
spectral peaks in the NMR spectra [11]. By offering this advantage, it improves the process of
biomarkers identification by NMR for diagnostic and monitoring applications.
There are three approaches used in metabolomic research: target analysis, metabolic
profiling and metabolic fingerprinting. Target analysis aims to quantitatively measure selected
metabolites i.e., specific biomarkers. Metabolic profiling is a non-targeted strategy that focuses
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on the study of a group of related metabolites or a specific metabolic pathway. Metabolite
fingerprinting does not aim to identify all the metabolites, but rather to compare patterns of
metabolites that change in response to the cellular pathway[10][16].
As a metabolite fingerprinting approach was employed for this project because more
detailed description is provided on this analytical platform. The goal of this approach was not to
identify each observed metabolite, rather to compare patterns or “fingerprints” of metabolites
that change in response to disease or for the purpose of this study, different risk factors for
diabetes. This technique can use a wide variety of biological matrices such as urine, plasma,
serum, saliva tissue or cells. Metabolic fingerprinting is considered a true “omics” approach,
because it can be applied to a wide range of metabolites [10]. The goal for many researchers is
to use metabolic fingerprinting as a diagnostic tool for evaluating differences in the signature
patterns between healthy and diseased subjects. This approach also allows for the evaluation of
therapeutic interventions by observing if the metabolic phenotype shifts back to the healthy state
after treatment. Although metabolic fingerprinting is an important platform to assess metabolic
differences in sample groups - metabolomics should not be used exclusively for fingerprinting
without identifying the metabolites that cause clustering of experimental groups. This will allow
a greater understanding of underlying mechanisms of action.

Thus, combining metabolite

fingerprinting and profiling is an important approach so that the metabolic signature can be
developed between different experimental groups and the metabolites causing the differences can
be identified. In this study we will use a non targeted metabolomics approach to investigate the
metabolite profiles of a heterogeneous non-diabetic human sample to determine which risk
factors, if any, are correlated with clustering and/or separation of the data.
Nuclear Magnetic Resonance (NMR)
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NMR is a powerful analytical tool for the characterization of chemical structure and
concentration based on nuclear properties of the atoms. NMR was first developed in1946 by
research groups at Stanford and M.I.T (USA) [20].

The data from the NMR analysis is

expressed in a spectrum as a representation of the nuclei’s chemical environment. When placed
inside a magnetic field the nuclei aligns itself according to whether they oppose or are parallel to
the applied magnetic field. The NMR spectrum shows at which shift the nuclei studied will
absorb energy- the more shielded a nucleus is, the higher the chemical shift. An NMR spectrum
is created by radiating the sample with a short pulse of high energy radio frequencies that excite
all nuclei. Transition of atomic nuclei between the excited energy state and a lower energy is
measured over a period of time as free induction decay (FID) signals. Since these FID signals are
time domain signal files, it is very difficult to differentiate between spectra from different
compounds so, the FID files are further transformed by Fourier transformation (Ft)
(mathematical algorithm) to a frequency domain [18]. After Ft the acquired spectrum can be
resolved into different peaks arising from different compounds or metabolites.
The NMR spectrum is plotted as a parts per million (ppm) value of the radiation
frequency. The number of signals shows how many different kinds of protons are present and
location of the signals shows how shielded or de-shielded the proton is. The intensity of the
signal shows the number of protons of that type. The nuclei of most interest in biology are 1 H,
13 C, 31 P, 15 N, 19 F because they have an odd spin number. Transition between these 2 states
can be brought about by absorption of energy which is provided by electro-magnetic radiation.
When this magnetic field is proportional to the correct level then the nucleus can absorb the radio
frequency. The amount of energy absorbed is proportional to the number of nuclei.
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This analytical tool is a popular platform for metabolic profiling because the technique is
non- destructive; requires little or no sample preparation; is rapid and provides highly
reproducible results and the spectra contains a wealth of information [11]. This is in contrast to
other techniques such as GC-MS, which requires pre-treatment of the specimen matrix,
derivitization and then an on-column separation of the products before any molecular
characterization can be done using the MS data [21]. In this study, we will use the 1H NMR to
investigate the metabolic profiles for potential differences based on risk factors for diabetes.
Multivariate Data Analysis (MVDA)
Data

obtained

from

NMR

is

complex

to

analyze

because

qualitative/quantitative information on several hundreds of metabolites.

it

contains

Multivariate data

analysis (MVDA) is employed to obtain meaningful information on disease and healthy samples
by differentiation of biofluid samples based on the difference in signals of multiple metabolites.
Due to the huge data sets obtained in metabolomics analysis, it is necessary to transform that raw
data into useful information.

The most common data reduction technique is Principal

Component Analysis (PCA). Data reduction using PCA is an example of an unsupervised
method which determines correlation differences among data sets based on how the observations
are different or similar to each other. This data reduction technique transforms the original data
into a set of ‘scores’ for each sample, measured with respect to the principal component axes
(loadings). The PC scores replace the original varieties and show maximum variability in the
data set. These PC are compared in multidimensional space to corresponding score values [22].
The data is visualized as a PCA score plot where each score is one observation or in the
case of NMR one score is one spectra [23]. The scores plots provide visualization and
summarization of the data often revealing clustering of similar samples, separation of different
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sample types, or the presence of outliers. The contribution of each individual variable to PC
scores can be calculated as a loading plot. Loading plots represent the variables that are
responsible for clustering or differentiating between the groups [24].
Partial Least Sqaure (PLS) is a regression extension of PCA, which is used to connect
two data matrices, X and Y, to each other by a linear multivariate model. This analysis is done to
determine the patterns in the data sets based on specific knowledge about the data. In this
supervised method one has to feed specific information about the data sets e.g. categorize the
data sets into different groups. PLS has become a standard tool for modeling linear relations
between multivariate measurements [22].
However, methods for data analysis and the sets of instruments used are diverse across
laboratories that practice comprehensive metabolic profiling. This lack of standardization in the
methodology increases the potential for reduced reproducibility of the findings. Often the
metabolic platform is driven by factors such as cost, personal experience, and specific research
goals [25]. Nevertheless, confidence in the obtained information is achieved by employing strict
criteria for sample collection, methods and statistical algorithms.
Metabolite quantification (Chenomx)
Chenomx is a metabolite database software that allows the identification and
quantification of metabolites by comparing to the NMR spectra. Prior to the availability of the
Chenomx software, once an unknown compound was determined, it was challenging task to
identify it and determine its biological significance of the metabolites. Chenomx provides a
database consisting of 292 quantified urinary metabolites [14]. KEGG (Kyoto Encyclopedia of
Genes and Genomes) is an online free website that explains all the known pathways that involve
particular metabolites [26]. As well, the Human Metabolome Database [27] is an electronic
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database containing information about the metabolites found in the human body. It is intended
for metabolomics application in clinical chemistry, biomarker discovery and general education.
This database contains over 7900 small molecules and provides information on metabolites from
humans including both water-soluble and lipid soluble metabolites as well as metabolites that
would be regarded as either abundant (> 1 uM) or relatively rare (< 1 nM)[27].
To summarize, metabolomics is a quantitative and qualitative analytical technique that
provides comprehensive information about metabolites. Samples for analysis can be obtained
non invasively. Metabolomics can be used to assess early biomarkers and distinguish between
healthy and diseased states. In the current study, we used metabolomics as a tool to evaluate the
differences in the metabolic profiles between persons with risk factors for diabetes.
DIABETES
Between 2010 and 2030, there will be an estimated 70% increase in the number of adults
with diabetes in developing countries and 20% increase in developed countries around the world
[28]. Diabetes is a complex disease [29], which is characterized by abnormal hepatic glucose
output, insulin resistance and impaired insulin production [30][31].

A position statement

published by The American Diabetes Association (ADA) (2011)[32] describes diabetes as a
“chronic illness that requires continuing medical care and ongoing patient self management
education and support to prevent acute complications and to reduce the risk of long term
complications”. For many individuals who are unaware of their chronic state of high blood
sugars, damage has started to occur before diagnosis. This chronic state of hyper-glycemia is
associated with damage, dysfunction and failure of several organs including the kidneys, eyes,
nerves and blood vessels [33].

11
Currently a small number of biomarkers are used for clinical assessment of diabetes and
may be insufficient to reflect the global variation in the pathophysiology [34]. Changes in
metabolic profiles which are a result of disease progression are a potential source of such
biomarkers [14][15][35][36].
Diabetes is diagnosed by the fasting plasma glucose (FPG) or the 2-h 75-g oral tolerance
test (OGTT) [37]. In 2010, ADA adopted the use of A1C test to diagnose diabetes of ≥6.5%
[38]. 1n 1997 and 2003, the Expert Committee on Diagnosis and Classification of Diabetes
Mellitus recognized an intermediate group of individuals whose glucose levels, did not meet the
criteria for diabetes diagnosis but were too high to be considered normal [39][40]. Elevated
blood glucose levels below the threshold for diabetes diagnosis also have clinical consequences.
These persons are defined as “prediabetes” and have been tested with an impaired fasting
glucose level of 100-125 mg/dl (5.6-6.9 mmol/l) or impaired glucose tolerance test 2 hours post
glucose values of 140-199 mg/dl (7.8-11.0 mmol/l)[32]. Individuals with IFG and/or IGT do not
have diabetes; however, they are at an increased risk for the future development of diabetes and
CVD [41]. IFG and IGT are strongly associated with obesity, dyslipidemia with high
triglycerides and/or low HDL cholesterol and hypertension [32].
In prospective studies, A1C has been used to predict the progression of diabetes. In a
systematic review including 44, 203 participants from 16 cohort studies those with an A1C
between 5.5 and 6.0% had a substantially increased risk of developing diabetes with a 5 year
incidence ranging from 9-25%. This review found that an A1C range of 6.0-6.5% had a 5-year
risk of developing diabetes 25-50% and relative risk 20 times higher compared with A1C of 5%
[42]. ADA now recommends the A1C test as diagnostic tool for diabetes [32]. As with IFG and
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IGT, elevated levels of A1C of 5.7-6.4% can be considered a predictor of increased risk for
future diabetes as well as CVD [37].
The ADA recommends that Testing for Diabetes in asymptomatic persons include:
Testing should be done at any age with a BMI ≥ 25 kg/m2 and/or have one or more
additional risk factors for diabetes which includes: physical inactivity, first-degree
relative with diabetes, high risk ethnicity, women who delivered a baby weighing >9 lbs
or were diagnosed with gestational diabetes, hypertension, HDL cholesterol level <35
mg/dl and/or a triglyceride level >250 mg/dl, women with polycystic ovarian syndrome,
A1C≥5.7%, IGT or IFG on previous testing, severe obesity, history of CVD.
In those without the risk factors listed, testing should begin at age 45 years;
To test for diabetes or assess risk for future diabetes, A1C, FPG, or 2-h 75 g OGTT is
appropriate; and
In those identified with increased risk for future diabetes, identify and if appropriate treat
other CVD risk factors.
Fortunately, the same testing and clinical assessment can be done for screening, diagnosis and
disease management. For many individuals, diagnosis of type 2 diabetes is not done until
complications appear and according to the ADA [26], one-fourth of all people in the U.S. may be
undiagnosed. Although the relatively low prevalence of diabetes in the general population
makes it unlikely that mass screening will be cost effective, testing for people with risk factors
for disease development is likely to result in more benefit than harm and will lead to overall cost
savings [43][44]. Mathematical modeling studies suggest screening independent of risk factors
beginning at age 30 or 45 years is a cost effective strategy [45]. Diabetes care accounts for about
2-7% of the total national health care budgets of western European countries [46].
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There are intervention strategies for individuals who are at increased risk for developing
diabetes that will significantly decrease the rate of onset for disease development. Risk factors
for disease progression include physical inactivity, overweight, elevated lipid levels, unhealthy
diet, ethnicity, family history of diabetes, smoking, ethnicity and family background. Many of
these risks factors are modifiable which means that a person has the ability to delay the onset of
disease progression. For many persons; however they do not display clinical symptoms of
disease development until complications begin to occur.
Metabolomics has the potential in theory and based on observation from studies, to find
early metabolic changes related to diabetes disease progression prior to many clinical symptoms.
Although metabolic analysis is still considered to be in its infancy many believe that
metobolomics strategies can have a pertinent impact on the discovery of clinical and
pharmacological biomarkers. Given this emerging technology that’s available, the increasing
burden of the condition worldwide, earlier identification of ‘at risk’ individuals beyond current
clinical markers is particularly important.
METABOLOMICS APPLIED TO DIABETES
Individuals with diabetes have many metabolic pathways that are likely affected and
presumably play a role in their overall metabolic dysfunction.

Characterization of the

pathophysiological alterations associated with the disease condition can be improved by
identification of biomarkers and pathways related to the disease progression [47].
Assessment of a biological system by means of global and non-targeted metabolic
profiling provides the investigator with molecular information that is close to phenotypes in
question because metabolites are a product of gene, mRNA and protein activity.
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According to Bain et al.[25], metabolomics application for diabetes provides advantages
compared to other ‘omics’ technologies (genomics, transcriptomics, proteomics) because:
1.

The Human Metabolome Database (HMDB)- Canada[27] currently lists approximately
6500 discrete small molecule metabolites which is a fraction of the estimated 25000
genes, 100 000 gene transcripts and 1 000 000 proteins;

2.

Metabolite concentration alterations are the net result of genomic, transcriptomic and
proteomic variability, therefore, providing the most integrated profile of biological status;
and

3.

Metabolomics is a precise tool for discerning mechanisms of action and possibly
toxicological effects of drug therapies.

Thus, metabolomics can reveal crucial information that is closely related to the current disease
state or therapeutic status.
Multivariate statistical analyses of the 1H NMR data from human, rat and mouse urinary
profiles demonstrate metabolic similarities among the three species, including responses
associated with disease progression of diabetes involving glucose metabolism, the tricarboxylic
acid (TCA) cycle and the nucleotide and methylamine metabolisms [48]. In a study, using rats
induced with diabetes NMR based metabolomics found differences in several metabolic
pathways including glucose metabolism, TCA cycle, the alanine pathway, the Cori cycle, the
acetate switch and choline metabolism [49]. Another study, with Zucker diabetic fatty rats, in
the pre diabetic state showed that there were decreased levels of plasma concentrations for
gluconeogenic amino acids, aspartate, serine, glutamine, glycine and histidine whereas, taurine,
alpha-aminoadipic acid, methionine, phenylalanine, tryptophans and branded chain amino acids
were increased. At the diabetic stage, a larger number of gluconeogenic amino acids had
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decreased plasma concentrations.

The study concluded that there is evidence that insulin

resistance alone is capable of bringing about many of the changes in amino acid metabolism
observed in diabetes [50].
Cross-sectional studies have documented differences in blood metabolite profiles before
and after glucose loading [25][27][51] and in obese versus lean human subjects [52]. These
studies have noted differences in levels C3 and C5 acylcarnitines, glutamine/glutatmate and
additional amino acids and other small molecules.

The observations from these studies

demonstrated the possibilities that alteration in plasma metabolite levels are affected before the
onset of diabetes and may be useful in the identification of ‘at risk’ individuals compared to
clinical markers. For example, in a study conducted by, Doorn et al., participants were given an
oral glucose tolerance test, and endogenous metabolites were compared between participants
with diagnosed diabetes compared to healthy individuals [53]. At baseline, there were diseaserelated metabolic differences between cases (diabetic subjects) and controls (non diabetic
subjects). The cases underwent a 2 week ‘wash-out’ period prior to providing baseline urine and
blood plasma samples. As a result, the differences in the metabolite concentrations were likely
attributable to the disease related differences in the metabolic profile.

In plasma, these

differences were related to variation in lipid concentrations and lactate, and decreased levels of
several amino acids.

In urine, there were differences in the amino acid concentrations.

Similarly, another study reported citrate and hippurate to be elevated in urine of diabetes subjects
vs. healthy controls using NMR spectroscopy [54].
In a study conducted by Wang et al., [55] metabolite profiles predicted the development
of diabetes in a nested case control study. Among 2422 individuals who had normal glycemic
levels, 201 developed diabetes over a 12 year period. Amino acids, amines and other polar
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metabolites were provided in baseline specimens using liquid chromatography tandem mass
spectroscopy. Cases and controls were matched for age, sex, body mass index and fasting blood
glucose. In the paired analysis of the two groups, five metabolites had p-values of 0.0001 or
smaller for the baseline differences. Of these metabolites the branched chain amino acids:
leucine, isoleucine and valine were able to predict future risk of diabetes. Thus, the study
observed that the fasting concentrations of amino acids were elevated up to 12 years prior to the
onset of diabetes. One advantage of this study was that the 12 year observation period showed
that the levels of amino acids were elevated prior to any alteration in insulin levels using
standard biochemical measures. The major finding of this study was that despite normal fasting
blood insulin levels amongst individuals, amino acid concentrations were predictive of diabetes
development. The researchers noted that one drawback of this study was that the sample
included individuals who were at “high” risk for diabetes disease progression because they
displayed factors such as obesity and elevated fasting glucose. As a result, the findings may be a
result of what would be expected in a high-risk cohort, not necessarily in a more heterogeneous
sample. Hence, the study further investigated a random sample of 400 participants who did not
have a diabetes or cardiovascular disease. This random cohort had a lower fasting glucose and
BMI compared to the original case -control group. After repeating the amino acid analysis, the
amino acid profile was still predictive of diabetes risk independent of standard diabetes risks;
however the relative risk was not as significant suggesting that the amino acid profiling shows
difference but may have greater value in ‘high’ risk individuals. The findings from this study do
support the theory that hyper aminoacidemia could be an early manifestation of insulin
resistance.
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Studies of branched chain amino acid supplementation in both animals [55] and humans
[56] observed that circulating amino acids may directly promote insulin resistance.

The

underlying cellular mechanisms may include activation of mTOR, JUN, IRS1 signaling
pathways in skeletal muscle [52][57].
Insulin resistance and impaired insulin secretion play a critical role in the pathogenesis of
type 2 diabetes and branch chain amino acids are modulators of insulin secretion [58][59][60].
Another mechanism that hyper aminoacidemia could promote diabetes is by hyperinsulinemia
leading to pancreatic α cell exhaustion.
A study published by Lyssenko et al., [61] in the New England Journal of Medicine
(2008), examined whether clinical or genetic factors or both could predict progression of
diabetes. The study found that the inclusion of known polymorphisms of diabetes progression
slightly improved the prediction of future disease development independent of clinical risk
factors. A family history of diabetes, an increased BMI, current smoking statues and elevated
liver enzymes were independent predictors of future type 2 diabetes. Obesity was a strong risk
factor for future diabetes, a risk that almost doubled in subjects with a family history.
A recent published study used a multiplatform approach of three different techniques
covering NMR and tandem mass spectroscopy [62].

The researchers observed that this

analytical approach detected perturbations of metabolic pathways linked to kidney dysfunction,
lipid metabolism and interaction with the gut microflora. The differences in the biochemistry
parameters between the diabetes and control group were modest; however with a limited sample
size, the study did detect many differences in metabolic profiles.
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A clinical challenge is to identify which individuals are ‘at risk’ and are most likely to
develop diabetes. The goal of this project was to provide further insights on the risk factors that
contribute to the differences in the metabolic profile of non-diagnosed adult subjects.
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SUMMARY AND SPECIFIC AIMS
To determine if metabolomics analytical techniques can differentiate between individuals
with different risk levels for diabetes, a trial is needed to identify differences in the metabolic
profiles of persons at risk for developing diabetes. The primary goal of this project is to conduct
a pilot study using current metabolomics techniques to identify differences in the metabolites
profiles of persons at risk for developing diabetes.
Before a definitive prospective trial is designed to answer these questions, we must first
address important questions regarding feasibility, sample size, and preliminary evidence of
differences in their metabolic profiles based on a person’s clinical assessment for developing
diabetes. Thus, we have conducted a pilot project to recruit subjects who pose a risk for
developing diabetes based on clinical and lifestyle conditions including: BMI, physical
inactivity, family history of diabetes, age, elevated blood pressure, elevated lipid profile, history
of gestational diabetes in men and women older than 45 years of age.
The rational for this proposed study is that metabolomics coupled with multivariate
analysis will observe differences in the metabolic profiles of individuals with or without risk
factors for development of type 2 diabetes.
In order to test the hypothesis, the following specific aims were established.
Specific Aim 1: To recruit and screen 50 persons with and without risk factors for development
of type 2 diabetes to determine the correlation among these risk factors.

Specific Aim 2: To investigate metabolic profiles for potential differences based on risk factors
for diabetes using metabolomics coupled with multivariate analysis.
This study will provide preliminary data to determine the differences, if any, in the metabolic
profiles of individuals with risk factors for developing of diabetes using metabolomics analysis.
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CHAPTER 2: MATERIALS AND METHODS
The study was approved by the Humans Investigation Committee at Wayne State
University and all participants were required to provide written consent (Appendix A).
Confidentiality of response was assured by assigning code numbers to each questionnaire and
biological samples, with the coding key only known to the project coordinator and principal
investigator. All data was kept in a locked file and the master list of names and corresponding
study numbers and consent forms will be shredded upon two years after completion of the study.
Written data from which identifying information has been removed will be retained for potential
future secondary analyses.
The first aim of the present study was to recruit and screen 50 persons with and without
risk factors for development of type 2 diabetes to determine if there were differences in their
metabolic profiles. A questionnaire was developed to collect information on risk factors for
diabetes in asymptomatic adult individuals. The study collected data including: BMI; physical
activity; diet, first-degree relative with diabetes; ethnicity; HDL lipid levels, fasting blood
glucose, anthropometric measurements and medical history. ADA further recommends that in
the absence of the above criteria, testing should begin at age 45 years. All participants did not
have a clinical diagnosis of diabetes; however, all subjects were over the age of 45 years which is
identified as a risk factor and many had other risk factors for diabetes.
Participant Recruitment
Participants were recruited in the community of Chatham, ON by utilizing the services of
local media and the Chatham-Kent Public Health Clinic Services to advertise the research project
with flyers (Appendix B). The study recruited participants on a continuous in May, June and
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July 2011. All assessments were conducted during 1- 60 minute visit. All assessments were
conducted by the project coordinator.
Participants who responded to recruitment strategies were screened by telephone to
determine eligibility. All participants were between the ages of 45 -65 years of age. The
exclusion criteria included individuals who were insulin-dependent or taking medication required
to control diabetes; had cancer requiring treatment in the past year; required use of lipid drugs;
unwillingness to provide plasma and urine samples and/or unwillingness to provide informed
consent.
Data Collection
Demographics and Medical Assessment- A standardized questionnaire (Appendix C) was
used to collect data on ethnicity, age, gender, medical history, family history of diabetes and
medications at baseline. Participants were asked to bring in medications and supplements to the
visit to verify medication and dosage.
Dietary Assessment- Participants completed a 24 hr diet recall with the project
coordinator.

From the information collected the project coordinator summarized the total

number of servings consumed from each of the food groups as recommended in the myplate
model produced by U.S Department of Agriculture [63].
Anthropometry and Body Composition- Height without shoes was measured using a
wall-mounted stadiometer to the nearest 0.1 cm. Weight was measured to the nearest 0.1 kg
using a calibrated and certified digital scale with the participant wearing light clothing without
shoes. Height and weight was used to calculate BMI. Waist circumference was measured using
a measuring tape placed around the subject at the level of the umbilicus. The subject was asked
to take a normal breath and the waist circumference was recorded when the subject breathes out.
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Blood Pressure was taken when the participant was relaxed and comfortably seated with the arm
well supported at heart level.
Blood and Urine Collection- After an overnight food deprivation, blood was collected by
a venous puncture and drawn by the project nurse into EDTA-containing tubes kept on ice.
After each clinic, samples were labelled and brought on ice to the University of Windsor where
the tubes were spun at 4500 rpm at 4°C for 20 minutes. Sodium azide (10%), gentamycin
sulphate (0.01%) and EDTA (10%) were added to plasma samples, which were brought back to
the Chatham-Kent Public Health Clinic Services and were stored at 4°C until study completion.
Participants provided 10-20 mL of mid-stream urine and10 mL of urine was transferred into a
plastic tube where sodium azide (10%) was added to the sample. The urine samples were
transferred into 3 – 2 mL tubes, labeled and stored at 4°C.
Once data collection was complete, blood and urine samples were shipped to Wayne
State University on dry ice.
Plasma Lipid Determination
Plasma samples were assayed for Total Cholesterol, HDL-C and Triglycerides using
enzymatic kits purchased from Pointe Scientific Inc. (Canton, MI). The procedure was followed
as described in the enzymatic kits protocol.
A total of 50 persons were screened and recruited; however, some of the samples of
plasma and/or urine were not used in the final analysis for the following reasons: the freezer was
unthawed and 6 plasma and urine samples were unthawed for 2 days and discarded; 4 blood
samples would not separate whole blood from plasma after 3 attempts; and 6 blood draws were
unsuccessful after 2 attempts from the project nurse. A total of 34 subjects had all of the study
parameters included in the analysis.
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The second aim of the study was to investigate metabolic profile differences based on risk
factors for diabetes using metabolomics coupled with multivariate analysis.
Statistical Analysis
NMR Spectroscopy
Urine samples were brought to room temperature and centrifuged at 10,000 rpm for 5
minutes. Samples were diluted with deuterium oxide (D2O) (Cambridge Isotope Inc., Andover,
MA) in the ratio of 1:1. NMR solvent (in D2O) containing 0.5 mM 3-(trimethylsilyl) -1
propanesulfonic acid sodium salt (TMSPS) (Sigma Aldrich Inc. St. Louis, MO) and 1mM
Imidazole (ACROS Organics, Thermo Fisher Scientific (NJ) were added to the diluted urine
sample in 9:1 ratio. Proton (1H) NMR Acquisition- NMR spectra were acquired using a 500MHz
Varian spectrophotometer. The free induction decay (FIDs) signals were acquired using a pulse
sequence sw = 6009.6, nt=64, d1=10s, satdly=990.0 ms, pw =9.5 us, mix-hst=100.0 ms, pw=9.5
us and 4.0 s acquisition.
Spectral Processing- FIDs were then processed using ACD/1D software (Advanced
Chemistry Development, Inc., Toronto, ON, Canada). All the FIDs were stacked together as a
group and then Fourier transformed to the spectra in the frequency domain. The whole spectra
were edited, auto-phased, auto-base lined and binned. Intelligent binning was used to divide the
edited spectra into 1000 bins. The spectra were digitized to a table of common integrals and
exported as a non-negative value text file for MultiVariate Analysis- Multivariate data analysis
(MVDA) (SIMCA P+ 12.0 Statistical software, Umetrics, Kinnelon, NJ).
Principle Component Analysis (PCA) and Partial Least Square (PLS) algorithms were used to
evaluate the data for similarities and differences in metabolomic profiles between the groups.
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CHAPTER THREE: RESULTS
The first objective of the study was to recruit and screen a total of 50 persons with and
without risk factors for development of type 2 diabetes to determine if there was a relationship
between the risk factors from participants.
Participant Demographics
A structured questionnaire was used to collect information on medical history and
anthropometric measurements, which included height, weight, waist and hip circumferences.
The total sample included 44 participants: 39 females and 5 male subjects. The age range was 45
to 64 years with an average age of 54 years. Of those participants, 98% were European Canadian
and 2% were Native Canadian.
Smoking Status
The proportion of the participants who were current smokers was 11%. Of the nonsmokers, 20% reported exposure to second hand in the home on a daily basis.
Physical Activity
On average, participants were physically activity for 125 ± 78 minutes. This was assessed
as a total for daily activity from vigorous, moderate or a combination of both. The percentage of
participants meeting the daily physical activity guidelines of 150 minutes/wk of moderate
activity, 75 minutes/wk of vigorous activity and/or combination of both activities was 71%.
Fruit and Vegetable Intake
The findings from the study indicated that 48% of subjects consumed 5 servings or more
of fruits and vegetables per day. The average intake was 4.6 ± 2.08 servings per day.
Alcohol Consumption
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According to the Low Risk Drinking Guidelines recommended by Health Canada,
drinking in moderation is defined as having no more than 2 drinks per day for women and no
more than 3 drinks per day for men. This definition is referring to the amount consumed on any
single day and is not intended as an average over several days. The number of subjects meeting
the low risk drinking guidelines was 89% (Figure 3:1). The mean weekly average for both males
and females of the study was 2.59 ±2.82 standard drinks.
Physical activity, alcohol, smoking and fruit and vegetable consumption were analysed
with bivariate correlations to determine if there was a relationship amongst these variables within
the study group. There was a significant positive relationship (p<0.05) found between the
average daily intake of fruit and vegetables and physical activity level (r=0.33). Physical activity
was also inversely correlated to alcohol intake, therefore participants with higher average levels
of physical activity were more likely to have lower alcohol consumption (r=-0.32) and this
correlation was significant (p<0.05).
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Average Alcoholic Drinks per week
11%
20%
5%
No Alcohol
1-2 drinks
3-5 drinks
6-7 drinks
30%

7+
34%

Figure 3:1 Average Alcoholic Drinks per week
The proportion of subjects who reported consumption of alcoholic beverages in a typical week. From the
information collected: 20% of participants reported consuming no alcohol on a weekly basis; 34% drank 1-2
standard drinks per week; 30% drank 3-5 drinks; 5% consumed 6-7 drinks per week; and 11% average consumption
was seven or more drinks per week.
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Anthropometric Measurement
Body Mass Index (BMI) is a ratio of weight to height (kg/m2). Waist to Hip ratio
estimates the distribution of subcutaneous and intra abdominal adipose and muscle tissue. Waist
circumference provides an index of the absolute amount of abdominal fat and adds to the
prediction of morbidity and mortality obtained from measuring BMI alone. BMI, waist to hip
ratio and waist circumference (WC) are anthropometric screening tools that can be used together
in order to identify individuals who are overweight or obese and are at an increased risk of
diabetes, cardiovascular disease and other related conditions. These measures should be
interpreted in conjunction with other measures of health risk as part of a complete individual
assessment.
BMI
The BMI provides ranges for a healthy weight (18.9-24.9kg/m2); overweight (2529.9kg/m2) and obese (30kg/m2 and above). BMI is a highly reliable and convenient measure
used to screen for obesity, but it does have some limitations that restrict its usefulness in certain
clinical settings. At the clinic visit participants’ weight and height was collected and the BMI
was calculated. The mean BMI was 27.6 ± 4.9 (Figure 3:2).
The average BMI for subjects aged 45-49 yrs was 28 kg/m2; 26.5 kg/m2 for those aged 50-59
and 30.3kg/m2 for subjects over the age of 60 years (Figure 3:3). BMI and age were
independent and the variables were unrelated to each other (r=0.20) (Figure 3:4).
Waist Circumference
The waist circumference correlates with visceral fat stores. Values greater than 102 cm
(40 inches) in men and 88 cm (35 inches) in women may indicate increased risk for
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cardiovascular disease and diabetes [64]. The average waist circumference was 91 cm (±14) and
45% of subjects had a measurement higher than recommendations.
Waist to Hip ratio
Waist to Hip ratio was calculated as an assessment of weight status for the subjects.
Ratios >1.0 in men and 0.8 in women may indicate increased risk for morbidity and mortality
[65]. Sixty eight percent of the participants had a waist to hip ratio either >1.0 in men or 0.8 in
women. The mean waist to hip ratio was 0.85 ± 0.067.
As would be expected, anthropometric measurements of BMI, waist to hip ratio and waist
circumference were strongly correlated with each other (Figure 3:5). This was more of an
assessment to determine accuracy of the measurements.
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Figure 3:2 Body Mass Index Classifications by Gender
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Figure illustrates the percentage of participants in each BMI classification by gender. The BMI distribution for
females was 36% classified as a normal weight, 41% overweight and 23% classified as obese. The BMI distribution
for males was that 60% of the males were in the overweight classification and 40% were classified as obese. Thus,
100% of the male sample was in the overweight or obese category
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Figure 3:3 Age and BMI
This figure shows the BMI average for each age group. Participants were aged 45-49 in Group 1; group 2 50-59 and
group 3 60-64 years.
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Figure 3:4 Correlation between Age and BMI
The correlation between age and BMI for this sample was weak (r=0.2). These variables were not related to each
other.

r=.91

15

20

25

30

35

40

45

50

140
130
120
110
100
90
80
70

Waist Circumference (cm)

Waist circumference (cm)

160
150
140
130
120
110
100
90
80
70

r=0.75

0.6

0.8

1

1.2

Waist to Hip Ratio

BMI kg/m2

Waist to Hip Ratio

1.4
1.2

r=0.91

1
0.8
0.6
15

20

25

30
35
40
BMI kg/m2

45

50

Figure 3:5 Anthropometric measurements BMI, waist to hip and waist circumference
Figure illustrates that the three measurements used to assess weight status were strongly correlated. Waist
circumference and waist to hip ratio showed the strongest correlation with BMI. All of these correlations were
statistically significant (p <0.01).
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Factors such as physical activity and dietary intake contribute to a healthy weight. Correlational
analysis was used to determine if these variables were related with weight measurements. As the
weight measurements collected were strongly associated with each other, BMI was used for this
analysis.
Physical activity showed a significant correlation with BMI (r=0.45)(p<0.01); however, fruit and
vegetable and alcohol consumption were not associated with BMI (Figure 3:6).
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Figure 3:6 Lifestyle Behaviours and BMI
Figure illustrates that BMI was negatively correlated with physical activity level which means that physical activity
increased by the amount of minutes per week, BMI decreased. This correlation was significant (p<0.01). However,
there was no correlation with fruit and vegetable intake and alcohol consumption.
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Lipids
Assessment of the lipid profile was included in the study because dyslipidemia is a risk
factor for diabetes progression. When a person is diagnosed with diabetes, lipid management is
important, as there is an increased prevalence of lipid abnormalities contributing to their risk of
CVD [37]. Dyslipidemia refers to abnormal levels of lipids in the blood which includes high
levels of total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), triglyceride (TG)
and/or low levels of high density lipoprotein cholesterol (HDL-C). Dyslipidemia can also be
described as hyperlipoproteinemia or hyperlipidemia (referring to abnormally high levels of TC,
LDL-C or TG) or hypercholesterolemia (referring to elevated TC and/or LDL-C)[66].
During clinic visit, a fasting blood sample was collected to measure, total cholesterol,
triglycerides and HDL cholesterol levels.

Recommendations from the American Heart

Association (AHA) were used as reference guidelines to assess normal and high values for lipid
cut off points. The mean TC in the study was 237 mg/dl (±55) and the proportion of participants
that were considered to have a high TC ≥240mg/dl was approximately 50%. The average value
for TG levels was 105 mg/dl (±47) and the proportion of persons with a high TG (≥150 mg/dl)
level was lower than those with high TC at 15%. The mean value for HDL-C was 65mg/dl
(±30). The percentage of participants with a low HDL-C ≤ 40 mg/dl was 18%.
LDL-C levels (or “bad” cholesterol, in the bloodstream) were calculated indirectly using
the Friedewald equation. This equation [LDL = total cholesterol – HDL – (triglycerides/5)]
calculates the concentration of LDL based upon the presence of total cholesterol, HDL and
triglyceride levels.

The mean concentration value for LDL-C was 151 mg/dl (±49). The

concentration of TG did not correlate with HDL-C (r=-0.13) or TC (r=0.14). However, HDL
and TC showed a significant correlation (r=0.47)(p<0.01) (Figure 3:7). LDL was not included in
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this regression analysis as the lipid value is derived from Cholesterol, HDL and triglyceride
concentrations; and therefore not recommended for regression analysis.
The changes in the lipid profiles are often accompanied by hypertension, obesity and
insulin resistance. The data collected in the study showed that there was a significant correlation
(p<0.05) between a fasting blood glucose and LDL-C (r=0.34), TC (r=0.37). The fasting blood
glucose was positively correlated TG (r=0.26); however this relationship was not significant
(Figure 3:8).
A systolic blood pressure reading showed a positive correlation with TG; however this
relationship was unrelated (Figure 3:9).
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Figure 3:7 The correlation between lipid values: TG, TC and HDL-C
As shown in this figure there was a very weak relationship between TG and HDL-C and TC concentrations. HDL-C
and TC values were significantly correlated (p<0.01).
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Figure 3:8 The Correlation between Fasting blood glucose and LDL-C, TC and TG concentrations
LDL and cholesterol were found to be significantly correlated (p<0.05) with fasting blood glucose. TG and fasting
blood glucose concentrations were correlated; however this relationship was not significant.
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Figure 3:9 The Correlation between Systolic blood pressure reading and TG concentrations
Blood pressure and TG levels are unrelated (r=0.25, p >0.05)

37
Higher levels of physical activity have been related to improved lipid profile and are
recommended to prevent the onset of diabetes and heart disease. From the analysis, there was a
slight; however, a negligible correlation between the level of physical activity and lipid values of
TG (r=-0.12), TC (r=-0.17) and LDL-C (r=-0.22) (Figure 3:10).
Increased blood pressure combined with hyperlipidemia contributes to an increased risk of heart
disease mortality compared to hyperlipidemia alone. There was an unrelated correlation (r=0.14)
found between triglyceride level and alcohol consumption for this population (Figure 3:11).
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The relationship between physical activity measured in minutes per week showed slight, negligible correlations to
the concentration level for lipids. This analysis did show an inverse relationship showing that as the number of
minutes increased being physical active, the concentration levels for LDL, cholesterol and triglycerides decreased.
The strongest correlation was noted to be LDL with an r =-0.22; however this correlation was not statistically
significant.
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Figure 3:11 The correlation between average weekly alcohol consumption and TG levels
This relationship between triglycerides and alcohol consumption was unrelated r=0.14.
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The 2006 AHA diet and lifestyle recommendations to improve lipid levels, advise that
individuals consume a diet rich in vegetables and fruits as these foods are rich in nutrients, low in
calories and high in fibre, therefore contributing to nutrient requirements without adding
substantial calories [67]. It is unknown whether CVD risk reduction is due to vegetables and
fruits themselves or the absence of other foods displaced from the diet. Diets rich in vegetables
and fruits have been demonstrated to lower blood pressure and improve other CVD risk factors
in short-term randomized trials. Furthermore, in longitudinal observational studies, regular
consumption of diets high in vegetables and fruits lower risk of developing CVD.

The

correlation between fruit and vegetable intake and lipid values was conflicting in this study.
Anticipated results were that as fruit and vegetable consumption increased, HDL would be
higher; however, this was not the relationship found from the results.

This correlation value;

indicated that the relationship between the variables were unrelated (Figure 3:12).
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Figure 3:12 The Correlation between Fruit and Vegetable Consumption and TG and HDL-C values
Fruit and Vegetable consumption showed an unrelated correlation with triglyceride level (r=0.18) and HDL
(r=0.19).
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Blood Pressure
The ADA identifies hypertension as a risk factor for developing diabetes. According to
the AHA there are several factors that can increase a person’s risk of developing high blood
pressure: family history, age, gender, physical inactivity, diet, overweight and obesity and
alcohol consumption. Other factors such as smoking, stress and sleep apnea may also be
associated with increased blood pressure [68]. Normal blood pressure was defined as a systolic
pressure below 120 mm HG and a diastolic pressure below 80 mm HG. Pre-hypertension was
defined as a systolic pressure between 120-139 mm HG and a diastolic between 80-89 mm HG.
High blood pressure was defined as systolic pressure of 140 mm HG or more, a diastolic
pressure 90 mm HG or more, or both. Hypertension diagnosis requires an average of several
readings; however for the purpose of this study, participants were categorized into Normal, PreHypertensive and Hypertensive based on the reading at the clinic visit or if they were taking
blood pressure lowering medication (Figure 3:13).
Blood Pressure and Age
Blood vessels lose flexibility with age which can contribute to increasing pressure
throughout the system, thus high blood pressure is typically associated with advancing age. For
subjects aged 45-49 years, 82% had a normal reading and 9% had a read which was considered
pre-hypertensive and 9% hypertensive. For participants aged 50-55 years, the proportion of
persons with a normal blood pressure reading was 67%, and 27% had a read which would
classify as hypertension. For those aged 55-59 years, 43% had a normal blood pressure reading,
43% pre-hypertensive and 14% hypertension. For individuals aged 60-64 years, 40% had a
normal BP read, 20% pre-hypertension and 40% hypertensive.

Correlational analysis
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demonstrated that there was a moderate correlation between blood pressure reading using the
systolic measurement and age (r=0.48) which was significant (p<0.01) (Figure 3:14).
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Figure 3:13 Proportion of participants classified as Normal, Pre-Hypertension and Hypertensive
As illustrated in the graph, over half 59% of the participants had a normal blood pressure, 16% were considered prehypertensive and 25% had a high blood pressure.
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Figure 3:14: Correlation between age and blood pressure
As age increased amongst the participants in the study, blood pressure readings for the systolic
measurement were higher. This correlation was statistically significant (p<0.01).
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Blood Pressure and Weight
Maintenance of a healthy BMI (18.5-24.9 kg/m2) and waist circumference (WC) (<88 cm
Female; <102 cm Male) is recommended to reduce blood pressure in hypertensive individuals.
Overweight, hypertensive individuals are advised to lose weight to decrease blood pressure. The
results from this study showed a relationship between BMI and blood pressure (Figure 3:15).
The correlation between BMI and blood pressure (r=0.30) was weakly positive and statistically
significant. (Figure 3:16).
Waist to Hip Ratio
Individuals who met the criteria for the recommended waist to hip ratio were more likely
to have a normal blood pressure reading.

Eighty six percent of subjects who met the

recommendations for the waist to hip ratio had a normal blood pressure; whereas 48% of
participants who were above the recommendations were classified as pre-hypertensive or having
hypertension (Figure 3:17). This correlation was not statistically significant.
Alcohol Consumption
Individuals with hypertension are at increased risk of developing diabetes. Similarly,
good systolic blood pressure control in individuals with diabetes reduces vascular complications.
Following the low risk drinking guidelines is recommended to reduce blood pressure for
individuals with hypertension.

The results from the study showed that there was an unrelated

correlation between alcohol consumption and blood pressure measurements (Figure 3:18).
Physical Activity
Accumulation of 30-60 minutes of dynamic exercise (such as walking, jogging, cycling
or swimming), at least four times per week in addition to routine activities of daily living is
associated with a reduction in blood pressure and may reduce the possibility of becoming
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hypertensive.

The number of minutes was indicated as a weekly average and a positive

relationship was determined with blood pressure (r=0.32) which was statistically significant
(p<0.05).
Fruit and Vegetable Consumption
A recently published study found that higher intake of fruits and vegetables, as part of a
healthy dietary pattern, may only contribute a modest beneficial effect to hypertension
prevention, possibly through improvement in body weight regulation [69].

The low sodium

DASH diet (i.e. high in fruit, vegetables and low fat dairy products; an emphasis on whole
grains; a low intake of cholesterol, saturated fat, red meats, and refined sugar; and the inclusion
of nuts, seeds and legumes several times a week) lowers blood pressure in normotensive
individuals [70]. The 24 hour dietary recall collected from the participants was not compared to
the recommendations of the DASH diet. However, information on daily fruit and vegetable
intake was obtained in the standard questionnaire. From the results, there was no correlation
between fruit and vegetable intake and blood pressure (r=0.03).
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Figure 3:15: The proportion of persons with normal, pre-hypertension and hypertension classified by BMI
For subjects with a normal weight BMI classification, 93% had a recommended blood pressure read and 7% were
considered pre hypertensive. Participants who had a BMI in the overweight classification were more likely to have a
pre hypertensive or hypertensive reading; with16% pre hypertensive and 26% hypertensive. The proportion of
subjects classified as obese an increased prevalence of pre-hypertension 28% and hypertension 40%.
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Figure 3:16 Correlation between blood pressure and BMI
As illustrated in this figure there was a correlation between BMI and blood pressure reading. Correlation was
significant (p <0.05).
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Figure 3:17 Proportion of participants with Normal, Pre-Hypertension and Hypertension classified by Waist
to Hip Ratio
Subjects who met the recommendations for waist to hip ratio had 86% of persons with a normal blood pressure
measurement and 14% had a measurement classified as hypertensive. Participants with a waist to hip ratio above
the recommendation of 1.0 for men and 0.80 for females had a greater proportion of the sample that were prehypertensive or hypertensive with a total of 54%. The correlation between waist to hip ratio and blood pressure was
not statistically significant.
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Figure 3:18 The Correlation between blood pressure and alcohol consumption
The correlation between blood pressure and alcohol consumption was unrelated (r=0.14).
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Figure 3:19 Correlation between Blood Pressure and Physical activity
There was a positive correlation with the weekly average in minutes for physical activity and the blood pressure
reading. This correlation was statistically significant p<0.05.
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Fasting blood glucose
The mean blood glucose level was 123 ± 27 mg/dl. The two variables that were statically
correlated with the fasting blood glucose were LDL and cholesterol. Other variables such as
physical activity, BMI, triglycerides and blood pressure showed weak correlations.
Summary of Aim 1
Studies have highlighted the association between insulin resistance (IR) and several
cardiovascular (CV) risk factors, including hypertension, obesity, dyslipidemia (i.e. high
triglyceride and low HDL-cholesterol) and glucose intolerance, in a cluster known as the
metabolic syndrome (MS). Many variables such as weight, family history, smoking status, diet
patterns, physical activity, sodium intake and alcohol consumption contribute to this cluster
known as metabolic syndrome increasing the complexity of the analysis and determination of
which factors are most connected. As shown in this study, it is difficult to identify which
individuals are most ‘at risk’ for developing diabetes as the risk factors can be independent to
one another but are often connected and overlapped.
The purpose of this project was to provide further insight on the risk factors that
contribute to the differences in the metabolic profile for non diabetic subjects. As a first step,
bivariate correlations were determined to investigate the linear relationship between the risk
factors and to determine how strong the relationship was between the variables.
Specific Aim 2
The objective of this aim was to study changes in urinary metabolism profiles based on
the varying risk factors for diabetes using 1D proton NMR. Urine was collected at base line and
stored at 4°C until further use. The samples were prepared and NMR FID files were acquired
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using 500 MHZ Magnet. The files were processed in ADC 1D NMR software and MVDA was
conducted using SIMCA P+ software.
Multivariate Data Analysis
The data files acquired from NMR were ready for MVDA analysis after processing.
PCA and PLS showed significant differences between the groups.
PCA
Unsupervised PCA was completed as a first step to determine if there were correlated
factors without the removal of outliers. This analysis is exploratory in nature to determine which
factors caused the greatest separation between the variables. There was a clustering of subjects
observed based on the dominating variable BMI. The score plot shows a separation when
subjects were divided into 2 groups: a BMI <27 kg/m2 and BMI

27 kg/m2 (Figure 3-20).

Partial Least Squares Regression Discriminate analysis (PLS-DA)
As the unsupervised analysis showed correlation with BMI, we further analyzed this with
PLS-DA, a supervised multivariate analysis algorithm. As shown in Figure 3-21, the somewhat
loose BMI separated clusters in PCA, became clearly distinct. Results indicate that in the interindividual urinary profiles are dominated by differences in their BMI. Thus, there are some
metabolites in the urine samples that are correlating with obesity/BMI.
To see the effect of BMI on various risk factors, we used PLS to correlate the urinary
metabolomic profiles with the risk factors collected. In the individual analysis, under Aim 1
BMI showed a strong correlation with the lipid profile (r2=0.52)(Figure 3-22). The urinary NMR
profile of the subjects showed good correlation between triglyceride concentration levels and the
lipid profile which included cholesterol, HDL, LDL and triglycerides.
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Figure 3:20 The PCA score plot BMI
The PCA score plot is showing some separation between the urinary metabolomics profiles of individuals with
normal (<27 kg m2) or high BMI (>27 kg/m2). Scores within the eclipse are significant to the model. Two outliers
(29, 43) are seen in this plot.
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Figure 3-21 PLS-DA Score Plot for BMI
PLS-DA score plot showing a clear separation between the urinary metabolomics profiles of subjects with normal
and high BMI.
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Figure 3:22 PLS Correlation Plot of 1 NMR Urinary metabolomics Profiles with BMI and Lipids
The figure shows a good correlation between the urinary metabolomics profile (x –axis) and Lipid concentration (yaxis). Since the metabolomic profiles were separated into two clusters based on BMI, this further indicted that
metabolite in the urinary profile related to BMI or obesity correlates with plasma lipid concentrations.
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Figure 3:23 PLS Correlation Plot of 1 HNMR Urinary Metabolomic Profiles with BMI and Blood Glucose
The figure shows correlation of urinary profiles between BMI and blood sugar in a non-diabetic population. The
figure depicts a good correlation of the metabolites in the urinary profile between BMI and blood glucose levels.
This shows that some metabolites in urine based on BMI could predict or correlate with fasting blood glucose, the
current biomarker for prediction of diabetes.
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Summary of Specific Aim 2
Utilizing NMR technique and use of SIMCA P+ (PCA score plot) differences were observed
between the urinary profiles based on BMI. Therefore, variability in the urinary profiles for this
study sample was evident for persons with a BMI >27 kg/m2.
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CHAPTER FOUR: DISCUSSION
The prevalence of diabetes is increasing epidemic proportions; with an estimated 17.5
million type 2 diabetic individuals in the United States. This costs the USA $174 billion [71]
and is considered to be one of the most pressing public health issues. To date, the exact cause of
type 2 diabetes remains unclear, however, it is considered to be an interplay between
environmental and genetic factors [72].

Emerging technologies for metabolomics analysis

increases the capacity to detect the onset of disease or ideally, the pre-diseased state.
The pathophysiology of diabetes is complex, and multifactorial.

In this relatively,

heterogeneous sample group of participants, we set out to investigate the impact of identified risk
factors related to the pathophysiology of diabetes in the metabolic profiles. Risk factors such as
age, obesity, physical inactivity, first degree relative with diabetes, high risk ethnicity,
hypertension, dyslipidemia, or impaired fasting glucose are factors related to the onset of
diabetes.

The ADA recommends that individuals over the age of 45 years have testing

completed to assess for diabetes. For this study, a standard questionnaire was developed to
collect information on these risk factors. The sample group did not have a diagnosis of diabetes,
but in addition to age, many of the participants had at least one risk factor increasing the risk for
future onset. Individuals may have risk factors such as obesity, dyslipidemia, elevated blood
sugars; however, often there is long pre-symptomatic phase prior to diagnosis. Early diagnosis is
imperative to improve a person’s outcome. In addition to current clinical markers, metabolomics
provides an opportunity to expand our knowledge of the causes and progression of this disease
and enhance treatment options for individuals. This is possible, by simultaneously investigating a
large and diverse set of metabolites.

This integrated approach allows the analysis and
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classification of metabolic states, reveals new pathways, and potentially improves the sensitivity
for detection of the altered state.
A first step in the analysis was to determine correlations among risk factors. Key
findings from this analysis were that there was a significant relationship between average daily
intake of fruit and vegetables and physical activity levels.

Physical activity was also

significantly correlated with decreased alcohol consumption. This was an expected finding, as
individuals who are physically active often display other healthy behaviours such increased fruit
and vegetable intake and moderate alcohol consumption. Physical activity was also strongly
associated with BMI which was an expected association, as individuals who report being active,
are more likely to have a lower body weight.
The characteristic features of dyslipidemia in humans with diabetes are high TG and
LDL-C concentrations and low HDL-C concentrations, whereas TC levels are not typically
increased in patients with diabetes. We conducted lipid analysis to determine the correlation to
the fasting blood sugar. The fasting blood sugar was significantly correlated with LDL-C and
TC concentrations.
Hypertension affects 60% of diabetic persons. High blood pressure often increases the
severity of diabetic complications such as diabetic retinopathy and kidney disease. Having
diabetes increases your risk of developing high blood pressure and other cardiovascular
problems, because diabetes adversely affects the arteries, predisposing individuals to
atherosclerosis, it can lead to high blood pressure, which if not treated, can lead to blood vessel
damage, stroke, heart failure, heart attack, or kidney failure. In this study sample, 41% of
participants were considered to be pre-hypertensive or have hypertension. Blood pressure was
significantly correlated to other measurements such as age, BMI and average weekly physical
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activity. However, in this study sample, blood pressure and fasting blood sugar were not found
to be strongly correlated.
The second part of the study was to conduct a non-targeted metabolomic analysis to
determine if there were differences in the metabolic profile and if so, what risk factors were
having the greatest impact on the metabolic signatures. The results showed that although this
group did not have a clinical diagnosis of diabetes, MVDA of 1H NMR data showed that the
greatest degree of differentiation was based on a BMI >27 kg/m2. The PCA scores plot showed
significant separation between the groups based on BMI. Each score or observation in the score
plot represents each individual urine 1H NMR data signifying that these groups were different
(PCA score plot) because of differences in the metabolite concentrations. The PLS technique
was used to assess correlation between the observed 1H NMR data and other risk factors such as
age. Our findings indicated that in the non-diabetic population being studied, differences in the
inter-individual urinary profiles were dominated by differences in the BMI. The PLS correlation
plot shows a good correlation of the urinary profiles between BMI and blood sugar in a nondiabetic population. Based on current clinical practices, this may be a relevant model for
prediction of risk for diabetes because BMI is a reliable and convenient measure and is currently
recommended as part of assessing diabetes risk. The correlation plots also demonstrated a good
correlation between the urinary metabolic profiles related to obesity also with triglycerides and
the lipid profile which included all of the lipid measurements.
1

H NMR proved to differentiate between the urinary metabolic profiles of individuals

who are overweight with a BMI > 27 kg/m2. To our knowledge this is the first example of 1H
NMR showing a strong separation between metabolic profiles based on a BMI of 27 kg/m2.
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Obesity showed the greatest degree of discrimination between the urinary profiles compared to
other risk factors.
It is understood, that the metabolite profile differs in lean individuals compared to obese
individuals; however, our study showed that metabolite profiles show differentiation when
individuals are in overweight classification (BMI 25-29.9 kg/m2) with a BMI >27 kg/m2.
BMI is a highly reliable and convenient measure used to screen for obesity. The effect of obesity
on the metabolic state; however, is still considered in its infancy. Obese individuals typically
have a greater degree of adipose tissue. This tissue releases bioactive molecules that influence
body weight, insulin sensitivity, blood pressure, circulating lipids and inflammation which leads
to metabolic diseases [73].
Diabetes can lead to pathological concentrations of several metabolites that can be
detected in urine. Analysis of 1H NMR in urine has identified a number of significantly changing
metabolites such high lactate citrate, glycine, alanine, hippurate, trimethylamine-N-oxide,
dimethlyaminecreatine, acetate, betaine and ketone bodies in diabetes

[74].

Comparison

between human and animal models (rat and mice) have shown similarities in the levels of
glucose, TCA cycle intermediate, polyols, amines and amino acids [48]. Studies have shown a
separation between T2DM patients compared with that of healthy subjects and identified the
metabolites contributing to the separation. For example, a study analyzed the differences in the
metabolite profile between healthy and non-medicated diabetic individuals who maintained good
daily blood glucose control by following ADA dietary guidelines. Metabolites that caused
significant separation between the groups included amino acids; methylamines; fatty acids and
nucleotides. This study highlighted the metabolic pathways that were affected which included:
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methylamine metabolism; TCA cycle; fatty acid metabolism; amino acid metabolism; and
nucleotide metabolism [74].
As shown in our study, a BMI >27 kg/m2 was the risk factor that caused the greatest
separation. There are several recent studies that have analyzed how obesity is affecting the
metabolite profile of humans. For example, one study analyzed differences between obese
insulin resistance and sensitive participants [75], another study compared the metabolome
between lean and diabetic individuals [62] and recently a comparison was conducted between
healthy lean and healthy obese individuals [55]. The benefit of the latter study, comparing
healthy lean versus healthy obese was that the risks factors that co-exist with obesity were
controlled so that this was a direct comparison between obesity biomarkers. The study revealed
novel and confirmed previously discovered metabolites that are markers for body fat mass
changes.
There are some challenges when utilizing metabolomics to study human population.
Firstly, unlike animal models which are in controlled laboratory conditions, human samples
display greater heterogeneity in their metabolic make-up. Factors such as genetics, environment
and lifestyle factors such as diet, physical activity levels, smoking status and intake of vitamins
and medications contribute to the heterogeneous nature when investigating human metabolite
profiles. Other limitations to this study are that a small sample limits generalizability of the
findings and the inability to conclude causality between the variables due to the use of a
correlational design. Despite these challenges and in a limited sample, metabolomics analysis
was able to differentiate between the metabolic profiles of these subjects. This project supports
the growing body of evidence that metabolomics using NMR spectroscopy is a sensitive
measurement to identify altered metabolite chemistry based on a person’s BMI. NMR analysis
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has its advantages in studying the metabolite profile as this tool offers a high through put method
at relatively low costs for high concentration biomarkers using non-invasive biofluids such as
urine. In a review of 1H NMR based metabolomics for investigating diabetes it concluded that:
“NMR spectroscopy is a reproducible and reliable means of measuring and understanding the
metabolic status of pathologies such as diabetes.” In future, this may be tool used to identify and
monitor people at risk for diabetes.
The ultimate goal of metabolomics is to define the metabolic signature of disease, versus
normality and use those signatures to gain insight into how the disease came to be and how to
treat. Further insight is needed to identify risk factors which have the greatest impact on the
metabolic signature and how these risk factors affect the biomarkers.
Future Directions
The next step is to identify and quantify the metabolites in chenomx. Further application
would be required to determine how obesity affects the chemistry of these metabolites.
Validation and estimation of these metabolites in the urinary profile would provide important
information about the progression of diabetes. The primary goal of this project was to obtain
preliminary findings to examine differences in the metabolomics profile of individuals with
varying level of risk for development of the diabetes. This study was considered a pilot for a
future project and was not designed to provide a high degree precision. However, this project
does provide a greater insight that metabolomics is a sensitive tool that is able to differentiate
between the metabolic profiles based on BMI, thus making it important to use the project
characteristics for a larger trial.
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APPENDIX A
Research Informed Consent
Title of Study: Use of Metabolomics to Investigate biomarker profiles as early risk factors for development of
T2DM/metabolic syndrome

Principal Investigator (PI):

Dr. Smiti Gupta, PhD
Department of Nutrition and Food Science
3009 Science Hall, Wayne State University
Detroit, MI 48202
(313) 577 2344

When we say “you” in this consent form, we mean you; “we” means the doctors and other staff.

Purpose
You are being asked to be in a research study that measures patterns in the markers for diseases
such as type II diabetes mellitus. You are eligible to take part in this study, based on your age,
health conditions and other health factors that are needed from participants. This study is being
conducted at Wayne State University in collaboration with the Chatham-Kent Public Health
Unit. The estimated number of study participants to be enrolled is about 50 people throughout
the Chatham-Kent area.
Please read this form and ask any questions you may have before agreeing to be in the
study.
In this research study, the goal is to identify metabolites, which are in the body as a product of
metabolism. Metabolites can be used to predict the progression of diseases such as type II
diabetes mellitus. From the blood and urine samples, a technique will be used to analyze the
metabolites to see if there are differences in these biomarkers for diseases. Using the analytical
technique, Nuclear Magnetic Resonance, we hope to discover similarities between participants
based on their risk factors for developing type II diabetes.
Study Procedures
If you agree to take part in this research study, you will be asked to visit the Chatham-Kent
Clinic Services for one 60-minute clinic visit. You will be asked to complete a questionnaire
with the research assistant and provide a blood and urine sample. The blood will be drawn and
blood pressure taken by a qualified Registed Nurse at the Chatham-Kent Public Health Clinic
Services. The study will collect 10 ml urine and 8 ml of blood. Other physical measures that will
be collected are: height, weight and hip circumference. The questionnaire will also require that
you provide information on medical history, dietary intake.
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The blood and urine samples will be analyzed at Wayne State University Chemistry Department
using the technique, Nuclear Magnetic Resonance spectroscopy.

Benefits
As a participant in this research study, there may/will be no direct benefit for you; however,
information from this study may benefit other people with similar health issues now or in the
future.
Risks
Blood samples will be obtained from your veins. Possible side effects of obtaining blood samples
are pain, bruising, bleeding, or infection at the blood draw site. Occasionally nausea,
lightheadedness or fainting may occur.
There may also be risks involved from taking part in this study that are not known to researchers
at this time.
Study Costs
Participation in this study will be of no cost to you.
Compensation
For taking part in this research study, you will be paid for your time and inconvenience by
receiving a $20 Gift Certificate to the local grocery store.
Research Related Injuries
In the event that this research related activity results in an injury, treatment will be made
available including first aid, emergency treatment, and follow-up care as needed. Cost for such
care will be billed in the ordinary manner to you or your insurance company. Wayne State
University or Chatham-Kent Public Health Clinic Services offers no reimbursement,
compensation, or free medical care. If you think that you have suffered a research related injury,
contact the PI right away at (313) 577 2344.
Confidentiality
All information collected about you during the course of this study will be kept confidential to
the extent permitted by law. You will be identified in the research records by a code name or
number. Information that identifies you personally will not be released without your written
permission. However, the study sponsor, the Human Investigation Committee (HIC) at Wayne
State University, or federal agencies with appropriate regulatory oversight [e.g., Food and Drug
Administration (FDA), Office for Human Research Protections (OHRP), Office of Civil Rights
(OCR), etc.) may review your records.
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When the results of this research are published or discussed in conferences, no information will
be included that would reveal your identify.
Voluntary Participation/Withdrawal
Taking part in this study is voluntary. You have the right to choose not to take part in this study.
Questions
If you have any questions about this study now or in the future, you may contact Dr. Smiti Gupta
or one of her research team members at the following phone number (313) 577 2344. If you have
questions or concerns about your rights as a research participant, the Chair of the Human
Investigation Committee can be contacted at (313) 577-1628. If you are unable to contact the
research staff, or if you want to talk to someone other than the research staff, you may also call
(313) 577-1628 to ask questions or voice concerns or complaints.
Consent to Participate in a Research Study
To voluntarily agree to take part in this study, you must sign on the line below. If you choose to
take part in this study you may withdraw at any time. You are not giving up any of your legal
rights by signing this form. Your signature below indicates that you have read, or had read to
you, this entire consent form, including the risks and benefits, and have had all of your questions
answered. You will be given a copy of this consent form.
_______________________________________________
Signature of participant

_____________
Date

_______________________________________________
Printed name of participant

_____________
Time

_______________________________________________
Signature of person obtaining consent

_____________
Date

_______________________________________________
Printed name of person obtaining consent

_____________
Time

Research Informed Consent
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APPENDIX C
Study #: _________________
Gender: M / F

Date of Birth: ____________
M/D/Y

Ethnicity: ___________

HEALTH RISK FACTORS
Do you smoke? Y



N



Have you smoked in the past 12 months? Y



N

If yes, how many cigarettes per day? __________
Please indicate if you are exposed to second hand smoke ? Y





N

How often do you participate in vigorous physical activity for 30-60 minutes?
(Vigorous activities include aerobics, fast cycling, walking, running, fast swimming or moving heavy objects)
5-6 times/week 

3-4 times/week 

1-2 times/week 

0-3 times/month



How often are you physically active for more than 30-60 minutes of moderate activity?
(Moderate activities include brisk walking, cycling, swimming, golfing and heavy gardening)
5-6 times/week 

3-4 times/week 

1-2 times/week 

0-3 times/month 

Is there anything that prevents you from being active? ______________________________________
On average, how many servings of fruits and vegetables do you typical eat everyday?
(1/2 cup of fresh or frozen, 1 cup leafy vegetables)
0-1 servings 

2-4 servings 

5-7 servings



8 or more servings 

How many alcoholic drinks do you consume in a typical week?
(The serving size for 1 drink is as follows: a regular 12 oz veer; 1.5 oz of hard liquor; a 5 oz glass of wine; a
regular 12 oz cooler)
None 

1-2 drinks



3-6 drinks 

7-10 drinks



10 + drinks 

MEDICAL HISTORY
Heart disease 
Cancer 
(family history)
Other: _____________________

Diabetes

Current medications? If yes, please list:
Allergies? If yes, please list:



Stroke 

Lung Disease 

ANTHROPOMETRIC DATA
Weight ________
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Height _________

Waist Circumference ________

Hip Circumference ______

BMI ___________
Waist/Hip Ratio _________

Systolic blood pressure (mmHg) _________

BIOCHEMICAL DATA
Fasting Blood Glucose ______

HDL ______

LDL

_____

Total Cholesterol

_______

Triglycerides _______

Food Group
Fruit and
Vegetables

Grains
Refined/Whole

Dairy and
Alternatives

Meat and
Alternatives

Other

Breakfast

AM

Lunch

PM

Dinner

HS

TOTAL
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ABSTRACT
THE USE OF METABOLOMICS TO INVESTIGATE BIOMARKERS PROFILES AS
POTENTIAL EARLY RISK FACTORS FOR DEVELOPMENT OF TYPE II DIABETES
by
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MAY 2012
Advisor: Dr. Smiti Gupta
Major: Nutrition and Food Science
Degree: Masters of Science
Type 2 Diabetes affects an estimated 17.5 million individuals in the United States and is
considered to be one of the most pressing public health issues of our time. To date, the exact
cause of type 2 diabetes remains unclear, however, it is considered to be an interplay between
environmental and genetic factors. Emerging technologies for metabolomics analysis increases
the capacity to detect the onset of disease or ideally, the pre-diseased state. Metabolomics has
the potential to find early metabolic changes related to diabetes progression prior to many
clinical symptoms. Although this technology is considered to be in its infancy many believe that
metabolomics strategies can have an impact on the discovery of pathological biomarkers for
diabetes progression. Given this emerging technology that is available, the increasing burden of
diabetes, earlier identification of ‘at risk’ individuals is particularly important.
The objective of this study was to determine if metabolomics analytical techniques could
identify differences in the metabolic profiles of persons at risk for developing diabetes. A
heterogeneous non-diabetic sample of persons with and without risk factors for development of
diabetes were recruited for this pilot study. A standard questionnaire was conducted to assess
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risk factors for diabetes. Fasting blood and urine samples were collected and frozen at -800 C.
Bivariate correlations were determined to investigate the linear relationship between the risk
factors. Urinary metabolite profiles were analyzed by proton nuclear magnetic resonance ( 1H
NMR) spectra. The processed, digitized NMR spectral data was analyzed using multivariate data
analysis software, SIMCA P+. Partial Least Squares Discriminant Analysis (PLS-DA) Score Plot
showed a clear separation between the urinary metabolomic profiles of subject based on a BMI ≥
27 kg/m2. PLS correlation plot showed a significant correlation between the urinary profiles
between BMI and fasting blood sugar in this non-diabetic population. The data suggests and in
agreement with the hypothesis, that 1H NMR was able to detect changes in the urinary profiles of
a non-heterogeneous non-diabetic population with the greatest degree of discrimination based on
BMI of 27 kg/m2. Based on current clinical practices, the identification of the metabolites
causing discriminating in the urinary profiles based on obesity may be a relevant focus for
predicting risk in a non-diabetic population.
This study was considered a pilot for a future project and was not designed to provide a
high degree of precision. However, this project does provide greater insight that metabolomics is
a sensitive tool that is able to differentiate between the metabolic profiles of human urinary
profiles based on BMI, thus making it important to use the project characteristics for a larger
trial.
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